Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Mar 30, 2011

Premium

PrognosDx Health announced that A. Franklin Rice has joined its board of directors. Rice is a member of BayBio Northern California's Life Science Association and "brings a wealth of experience in finance and administration to PrognosDx's board of directors," the company said in a statement.

Rice is currently the chief financial officer of the stem cell-based drug company VistaGen Therapeutics. He has held various positions in the biotech industry for 20 years.


According to documents filed with the US Securities and Exchange Commission, Genomic Health announced that Brook Byers will retire from its board of directors as of June 9. Byers has been a member of Genomic Health's board since 2001.

Byers is a senior partner at Kleiner Perkins Caufield & Byers. Since becoming a venture capital investor in 1972, he as been intimately involved with launching more than fifty technology companies.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.